Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.68 |
| ▸ | CTSD | P07339 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109631 | 1.00 | BACE1 (0.68) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL2516513 | 0.86 | BACE1 (0.66) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL2524972 | 0.86 | BACE1 (0.66) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL17201843 | 0.86 | BACE1 (0.63) | BACE1CTSDKCNH2 | |
| SCHEMBL17201841 | 0.86 | BACE1 (0.63) | BACE1CTSDKCNH2 | |
| SCHEMBL17201842 | 0.85 | BACE1 (0.61) | BACE1CTSDKCNH2 | |
| SCHEMBL17201840 | 0.85 | BACE1 (0.61) | BACE1CTSDKCNH2 | |
| SCHEMBL2518103 | 0.85 | BACE1 (0.87) | BACE1CTSDCTSEBACE2 | |
| SCHEMBL2518099 | 0.85 | BACE1 (0.87) | BACE1CTSDCTSEBACE2 | |
| SCHEMBL16109701 | 0.83 | BACE1 (0.68) | BACE1CTSDCTSEBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 2116/4885KCNH2 3083/4885 |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 2039/4885KCNH2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.